Tokyo Tape
Sign in
← ASKA Pharmaceutical Holdings

Annual report

4886.TEDINET S100R645
Period2022-04-01 → 2023-03-31
Filed2023-06-27
StandardJapan GAAP
ConsolidatedYes
Data checks22 of 22 passed
Key figures · 72
MetricValuePeriodScopeSource row
Revenue¥60.5bn2022-04-01 → 2023-03-31Cons.Net sales
Revenue¥56.6bn2021-04-01 → 2022-03-31Cons.Net sales
Operating income¥5.1bn2022-04-01 → 2023-03-31Cons.Operating income
Operating income¥4.8bn2021-04-01 → 2022-03-31Cons.Operating income
Ordinary income¥5.2bn2022-04-01 → 2023-03-31Cons.Ordinary income
Ordinary income¥4.9bn2021-04-01 → 2022-03-31Cons.Ordinary income
Profit before tax¥5.4bn2022-04-01 → 2023-03-31Cons.Income before income taxes
Profit before tax¥6.2bn2021-04-01 → 2022-03-31Cons.Income before income taxes
Net income (owners)¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent
Net income¥4.2bn2022-04-01 → 2023-03-31Cons.Profit loss
Net income¥4.3bn2021-04-01 → 2022-03-31Cons.Profit loss
Total assets¥87.1bnat 2023-03-31Cons.Assets
Total assets¥83.3bnat 2022-03-31Cons.Assets
Total liabilities¥32.6bnat 2023-03-31Cons.Liabilities
Total liabilities¥34.4bnat 2022-03-31Cons.Liabilities
Net assets / equity¥54.5bnat 2023-03-31Cons.Net assets
Net assets / equity¥48.9bnat 2022-03-31Cons.Net assets
Net assets / equity¥44.5bnat 2021-03-31dCons.Net assets
Cash and deposits¥14.5bnat 2023-03-31Cons.Cash and deposits
Cash and deposits¥12.1bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥17.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥17.1bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥10.5bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥3.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥2.8bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.1bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investment activities
Investing cash flow¥6.7bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investment activities
Financing cash flow−¥1.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥3.0bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities
EPS (basic)¥150.082022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥151.222021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
Net assets per share¥1,928.14at 2023-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥1,734.8at 2022-03-31Cons.Net assets per share (5-year summary)
Equity ratio62.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.7%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
ROE8.2%2022-04-01 → 2023-03-31Cons.Rate of return on equity (5-year summary)
ROE8.8%2021-04-01 → 2022-03-31Cons.Rate of return on equity (5-year summary)
Employees747at 2023-03-31Cons.Number of employees
Employees777at 2022-03-31Cons.Number of employees
Revenue¥1.7bn2022-04-01 → 2023-03-31StandaloneOperating revenue1
Revenue¥1.4bn2021-04-01 → 2022-03-31StandaloneOperating revenue1
Operating income¥658m2022-04-01 → 2023-03-31StandaloneOperating income
Operating income¥717m2021-04-01 → 2022-03-31StandaloneOperating income
Ordinary income¥603m2022-04-01 → 2023-03-31StandaloneOrdinary income
Ordinary income¥717m2021-04-01 → 2022-03-31StandaloneOrdinary income
Profit before tax¥603m2022-04-01 → 2023-03-31StandaloneIncome before income taxes
Profit before tax¥717m2021-04-01 → 2022-03-31StandaloneIncome before income taxes
Net income¥591m2022-04-01 → 2023-03-31StandaloneProfit loss
Net income¥682m2021-04-01 → 2022-03-31StandaloneProfit loss
Total assets¥41.6bnat 2023-03-31StandaloneAssets
Total assets¥41.3bnat 2022-03-31StandaloneAssets
Total liabilities¥630mat 2023-03-31StandaloneLiabilities
Total liabilities¥606mat 2022-03-31StandaloneLiabilities
Net assets / equity¥40.9bnat 2023-03-31StandaloneNet assets
Net assets / equity¥40.7bnat 2022-03-31StandaloneNet assets
Cash and deposits¥1.1bnat 2023-03-31StandaloneCash and deposits
Cash and deposits¥820mat 2022-03-31StandaloneCash and deposits
EPS (basic)¥20.952022-04-01 → 2023-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥23.792021-04-01 → 2022-03-31StandaloneBasic earnings loss per share (5-year summary)
Dividend per share¥162022-04-01 → 2023-03-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥152021-04-01 → 2022-03-31StandaloneDividend paid per share (5-year summary)
Net assets per share¥1,447.55at 2023-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥1,443.94at 2022-03-31StandaloneNet assets per share (5-year summary)
Equity ratio98.5%at 2023-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio98.5%at 2022-03-31StandaloneEquity to asset ratio (5-year summary)
ROE1.5%2022-04-01 → 2023-03-31StandaloneRate of return on equity (5-year summary)
ROE1.7%2021-04-01 → 2022-03-31StandaloneRate of return on equity (5-year summary)
Shares issued30,563,199at 2023-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued30,563,199at 2022-03-31StandaloneTotal number of issued shares (5-year summary)
Employees79at 2023-03-31StandaloneNumber of employees
Employees74at 2022-03-31StandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 55
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsemployeesat 2023-03-3114 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2023-03-31¥298m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2023-03-31¥220m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2023-03-31¥77m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2023-03-31¥42m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2023-03-31−¥6m
Reconciling Itemsreconcilingdepreciation2022-04-01 → 2023-03-31¥481m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2023-03-31−¥77m
Reconciling Itemsreconcilingsegment assetsat 2023-03-31¥43.9bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2023-03-31−¥1.1bn
Animal Health Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥4m
Animal Health Businessreportable segmentemployeesat 2023-03-3136 pure
Animal Health Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥6.7bn
Animal Health Businessreportable segmentsegment assetsat 2023-03-31¥3.0bn
Animal Health Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥409m
Pharmaceutical Businessreportable segmentdepreciation2022-04-01 → 2023-03-31¥2.5bn
Pharmaceutical Businessreportable segmentemployeesat 2023-03-31610 pure
Pharmaceutical Businessreportable segmentrevenue2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentrevenue external2022-04-01 → 2023-03-31¥53.6bn
Pharmaceutical Businessreportable segmentsegment assetsat 2023-03-31¥40.1bn
Pharmaceutical Businessreportable segmentsegment profit2022-04-01 → 2023-03-31¥5.8bn
Total Of Reportable Segments And Otherssegment totaldepreciation2022-04-01 → 2023-03-31¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2023-03-31¥60.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2023-03-31¥77m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2023-03-31¥43.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2023-03-31¥6.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2022-03-31¥259m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2022-03-31¥185m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2022-03-31¥73m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment assetsat 2022-03-31¥90m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2022-03-31−¥16m
Reconciling Itemsreconcilingdepreciation2021-04-01 → 2022-03-31¥136m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2022-03-31−¥73m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2022-03-31−¥73m
Reconciling Itemsreconcilingsegment assetsat 2022-03-31¥37.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2022-03-31−¥653m
Animal Health Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥4m
Animal Health Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥5.6bn
Animal Health Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥5.6bn
Animal Health Businessreportable segmentsegment assetsat 2022-03-31¥3.0bn
Animal Health Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥376m
Pharmaceutical Businessreportable segmentdepreciation2021-04-01 → 2022-03-31¥2.5bn
Pharmaceutical Businessreportable segmentrevenue2021-04-01 → 2022-03-31¥50.8bn
Pharmaceutical Businessreportable segmentrevenue external2021-04-01 → 2022-03-31¥50.8bn
Pharmaceutical Businessreportable segmentsegment assetsat 2022-03-31¥42.9bn
Pharmaceutical Businessreportable segmentsegment profit2021-04-01 → 2022-03-31¥5.1bn
Total Of Reportable Segments And Otherssegment totaldepreciation2021-04-01 → 2022-03-31¥2.6bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2022-03-31¥56.7bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2022-03-31¥56.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2022-03-31¥73m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2022-03-31¥46.0bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2022-03-31¥5.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,440
ItemContextValueUnit
Interest income noiPrior1YearDuration0JPY
Interest income noiCurrentYearDuration0JPY
Dividends income noiPrior1YearDuration258000000JPY
Dividends income noiCurrentYearDuration338000000JPY
Other noiPrior1YearDuration120000000JPY
Other noiCurrentYearDuration94000000JPY
Non operating incomePrior1YearDuration379000000JPY
Non operating incomeCurrentYearDuration433000000JPY
Interest expenses noePrior1YearDuration56000000JPY
Interest expenses noeCurrentYearDuration50000000JPY
Foreign exchange losses noePrior1YearDuration11000000JPY
Foreign exchange losses noeCurrentYearDuration43000000JPY
Loss on disposal of noncurrent assets noePrior1YearDuration43000000JPY
Loss on disposal of noncurrent assets noeCurrentYearDuration52000000JPY
Expenses of inactive non current assets noePrior1YearDuration155000000JPY
Expenses of inactive non current assets noeCurrentYearDuration53000000JPY
Contribution of esop trust noePrior1YearDuration－JPY
Contribution of esop trust noeCurrentYearDuration51000000JPY
Other noePrior1YearDuration27000000JPY
Other noeCurrentYearDuration57000000JPY
Non operating expensesPrior1YearDuration294000000JPY
Non operating expensesCurrentYearDuration308000000JPY
Ordinary incomePrior1YearDuration4880000000JPY
Ordinary incomeCurrentYearDuration5232000000JPY
Gain on sales of noncurrent assets eiPrior1YearDuration9425000000JPY
Gain on sales of noncurrent assets eiCurrentYearDuration－JPY
Gain on sales of investment securities eiPrior1YearDuration－JPY
Gain on sales of investment securities eiCurrentYearDuration124000000JPY
Other eiPrior1YearDuration258000000JPY
Other eiCurrentYearDuration－JPY
Extraordinary incomePrior1YearDuration9683000000JPY
Extraordinary incomeCurrentYearDuration124000000JPY
Impairment loss elPrior1YearDuration5953000000JPY
Impairment loss elCurrentYearDuration－JPY
Loss on valuation of investment securities elPrior1YearDuration1151000000JPY
Loss on valuation of investment securities elCurrentYearDuration－JPY
Contract termination fees elPrior1YearDuration870000000JPY
Contract termination fees elCurrentYearDuration－JPY
Other elPrior1YearDuration425000000JPY
Other elCurrentYearDuration－JPY
Extraordinary lossPrior1YearDuration8400000000JPY
Extraordinary lossCurrentYearDuration－JPY
Income before income taxesPrior1YearDuration6163000000JPY
Income before income taxesCurrentYearDuration5357000000JPY
Income taxes currentPrior1YearDuration983000000JPY
Income taxes currentCurrentYearDuration1108000000JPY
Income taxes deferredPrior1YearDuration890000000JPY
Income taxes deferredCurrentYearDuration10000000JPY
Income taxesPrior1YearDuration1873000000JPY
Income taxesCurrentYearDuration1118000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 22 of 22 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identitynon_consolidated 2022-03-31pass
balance sheet identitynon_consolidated 2023-03-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsnon_consolidated 2022-03-31pass
statement vs summary · net assetsnon_consolidated 2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2022-03-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2023-03-31pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2022-03-31pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenueconsolidated 2021-04-01/2022-03-31pass
statement vs summary · revenueconsolidated 2022-04-01/2023-03-31pass
statement vs summary · revenuenon_consolidated 2021-04-01/2022-03-31pass
statement vs summary · revenuenon_consolidated 2022-04-01/2023-03-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsnon_consolidated 2022-03-31pass
statement vs summary · total assetsnon_consolidated 2023-03-31pass